Adenosine and Dipyridamole interaction
Adenosine and Dipyridamole: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Dipyridamole label · effective 2026-04-29
Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
Adjustment of adenosine dosage may be necessary.
Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist.
From the Adenosine label · effective 2025-01-03
Nucleoside transport inhibitors such as dipyridamole can increase the activity of adenosine ( 7.1 )
The vasoactive effects of adenosine are potentiated by nucleoside transport inhibitors such as dipyridamole.
The safety and efficacy of adenosine in the presence of dipyridamole has not been systematically evaluated.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.